Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a biotechnology company with a strong focus on research and development. The company leverages its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs that target viral infections and liver diseases. Based in Watertown, Massachusetts, Enanta is at the forefront of developing novel inhibitors aimed at combating the hepatitis C virus (HCV), among other conditions.
Enanta's portfolio includes several classes of direct-acting antiviral (DAA) inhibitors, such as protease inhibitors, NS5A inhibitors, and nucleotide polymerase inhibitors. These are complemented by a host-targeted antiviral (HTA) inhibitor class specifically designed against cyclophilin. One of the company's most notable achievements is the development of paritaprevir, a lead protease inhibitor that is a key component of AbbVie's approved HCV treatment regimen.
In addition to HCV, Enanta is actively pursuing treatments for other serious conditions. The company has a preclinical program targeting non-alcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage due to fat buildup. Enanta's research also extends to hepatitis B and the respiratory syncytial virus (RSV), broadening its impact on viral and liver diseases.
Enanta operates in partnership with AbbVie, which markets its protease inhibitors, while other promising drug candidates are progressing through the development pipeline. The company's commitment to innovation and strategic collaboration positions it as a significant player in the biotech industry.
Enanta Pharmaceuticals announces positive results from the final Phase 1b data of EDP-514, a new hepatitis B virus core inhibitor. At 800 mg, EDP-514 was shown to be safe and well-tolerated over 28 days, with robust antiviral activity reflected in a 3.5 log decline in HBV DNA in viremic patients. EDP-514's pharmacokinetics support once-daily oral dosing, paving the way for combination therapy strategies. The data was presented at The Liver Meeting® 2021, showcasing the potential of EDP-514 for chronic HBV treatment.
Enanta Pharmaceuticals (NASDAQ:ENTA) has released preclinical data for EDP-235, an oral protease inhibitor targeting COVID-19. The data, presented at the ISIRV-WHO Virtual Conference, shows EDP-235's potent inhibition of SARS-CoV-2, with an IC50 of 5.8 nM and effective action against variants. The drug demonstrated promising pharmacokinetic properties, including 95% oral bioavailability and a projected half-life of 16 hours, indicating potential for once-daily dosing. Enanta plans to advance EDP-235 into clinical studies in early 2022.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that new preclinical data for EDP-235, its lead oral protease inhibitor for COVID-19, will be presented at the ISIRV-WHO Virtual Conference from October 19-21, 2021. The poster presentation titled “EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19” will be showcased on October 19 at 8:00 a.m. CET, presented by Li-Juan Jiang, Ph.D. The company continues to focus on developing antiviral treatments, supported by royalties from its collaboration with AbbVie for hepatitis C virus products.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat on October 13, 2021, at 3:30 p.m. ET during the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference. A live webcast of the presentation can be accessed on Enanta’s website, with replays available for 30 days post-event. Enanta focuses on small molecule drug discovery for viral infections and liver diseases, including candidates for respiratory syncytial virus, hepatitis B virus, and COVID-19.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced the selection of EDP-305 1.0 mg as the optimal dose after an interim analysis of the ARGON-2 Phase 2b study. The company will discontinue this trial evaluating EDP-305 as a monotherapy in favor of pursuing combination therapies for non-alcoholic steatohepatitis (NASH) through an out-licensing strategy. Data from EDP-297 indicated it is not substantially differentiated from EDP-305. Enanta aims to redirect resources toward developing treatments for hepatitis B and respiratory diseases.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced two poster presentations for its novel pangenotypic hepatitis B virus (HBV) core inhibitor EDP-514 at The Liver Meeting® 2021 from November 12-15, 2021. The data highlight preliminary results from a 28-day Phase 1b study in patients with chronic HBV. The presentations focus on EDP-514's ability to significantly reduce HBV DNA and RNA in viremic patients. These findings could advance Enanta's efforts in developing effective treatments for chronic HBV infections.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announces that Jay R. Luly, Ph.D., President and CEO, will participate in two virtual investor conferences in September 2021. These include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 and the Baird 2021 Virtual Global Healthcare Conference on September 14 at 12:15 p.m. ET. Webcasts will be available on Enanta's website. The company focuses on discovering small molecule drugs for viral infections and liver diseases, leveraging royalties from hepatitis C products developed with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) has elected Yujiro S. Hata to its Board of Directors. Hata brings over 20 years of experience in developing innovative therapies and has held key positions in several biotechnology companies. His expertise is expected to enhance Enanta's strategic direction, particularly in advancing combination therapies for viral infections and liver diseases. Hata is currently the Founder and CEO of IDEAYA Biosciences, with a track record of successful partnerships and acquisitions in the biotechnology sector.
Enanta Pharmaceuticals has initiated its Phase 1 clinical trial for EDP-721, an innovative oral hepatitis B virus (HBV) RNA destabilizer. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of EDP-721 in healthy volunteers followed by chronic HBV patients. The company envisions that EDP-721, when combined with existing treatments, could lead to an all-oral regimen for achieving functional cures for HBV. Preliminary data from the first part of the study is expected in early 2022, highlighting Enanta's ongoing commitment to developing groundbreaking treatments for viral infections.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported strong fiscal third-quarter results for the period ending June 30, 2021, with total revenues of $21.6 million, up from $18.7 million in 2020. The increase is attributed to royalty revenue from AbbVie's HCV regimen, MAVYRET. The company faced a net loss of $24.0 million compared to $14.3 million the previous year, largely due to increased research and development costs. Enanta is advancing its pipeline, preparing for Phase 1 studies of EDP-235 and EDP-721, amidst a strong cash position of $372.5 million.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
What is the focus of Enanta Pharmaceuticals?
Where is Enanta Pharmaceuticals located?
What are some of the diseases Enanta targets?
What is paritaprevir?
Does Enanta collaborate with other companies?
What is Enanta’s approach to drug discovery?
What is NASH?
What are DAAs?
What is an HTA inhibitor?
What makes Enanta significant in the biotech industry?
